Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCEs (elranatamab, SAR442257), or activated T cells, and analyzed by flow cytometry. CD45 upregulation was validated in patient samples before and after idecabtagene vicleucel therapy (anti-BCMA CAR T-cell therapy), and by using in an in vivo mouse model of disseminated MM...Mechanistic studies implicated secreted HSP70, while bulk RNA-sequencing revealed increased LAG-3, IFN-γ signaling, and PD-L1 expression. These findings suggest T cell-redirecting therapy (TCRT) drives an immuno-evasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed/refractory MM.

13 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)

PD-L1 expression

Elrexfio (elranatamab-bcmm) • SAR442257 • Abecma (idecabtagene vicleucel)

26d

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL (clinicaltrials.gov)

P1, N=47, Completed, Sanofi | Active, not recruiting --> Completed

26 days ago

Trial completion • First-in-human

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

SAR442257

2ms

MDX-2001-101: Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=285, Recruiting, ModeX Therapeutics, An OPKO Health Company | N=115 --> 285

2 months ago

Enrollment change • First-in-human

2ms

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer (clinicaltrials.gov)

P1/2, N=228, Recruiting, Regeneron Pharmaceuticals | N=370 --> 228 | Trial completion date: Jan 2027 --> Mar 2030 | Trial primary completion date: Jan 2027 --> Mar 2030

2 months ago

Enrollment change • Trial completion date • Trial primary completion date

nezastomig (REGN5678)

2ms

ATHENA-1: A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)

P1, N=107, Recruiting, Regeneron Pharmaceuticals | Trial completion date: May 2029 --> Jan 2030 | Trial primary completion date: Jun 2027 --> Feb 2029

2 months ago

Trial completion date • Trial primary completion date

Ordspono (odronextamab) • REGN5837

2ms

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)

P1, N=355, Recruiting, Janssen Research & Development, LLC | N=250 --> 355

2 months ago

Enrollment change

apalutamide • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • JNJ-6143 • pasritamig (JNJ-8343)

2ms

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC (clinicaltrials.gov)

P1, N=138, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting

2 months ago

Enrollment open • First-in-human

DLL3 (Delta Like Canonical Notch Ligand 3)

DLL3 expression

2ms

Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=400, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • MUC17 (Mucin 17)

MSI-H/dMMR

alveltamig (ZG006)

2ms

R17372-HM-2493: A Trial to Study if REGN17372 in Combination with Linvoseltamab is Tolerable for Adult Participants with Relapsed/Refractory Multiple Myeloma (2025-522776-93-00)

P1, N=26, Not yet recruiting, Regeneron Pharmaceuticals Inc.

2 months ago

New P1 trial • First-in-human

Lynozyfic (linvoseltamab-gcpt)

2ms

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)

P1/2, N=150, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting

2 months ago

Enrollment open • First-in-human

Lynozyfic (linvoseltamab-gcpt)

3ms

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P2, N=300, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

MUC16 (Mucin 16, Cell Surface Associated)

ubamatamab (REGN4018) • Kevzara (sarilumab)